Skip to content

Evaluation of the Effects of a Sensory Room on Vagal Activity and Attention Function in Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Crossover Trial

Evaluation of the Effects of a Sensory Room on Vagal Activity and Attention Function in Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Crossover Trial - Evaluation of the Effects of a Sensory Room in Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Crossover Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059976
Enrollment
20
Registered
2025-12-15
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

[Intervention using the Sensory room] A Sensory room measuring approximately 5.0 m^2 x 2.0 m was constructed in the Human Health Sciences at Kyoto University. One participant and one occupational the

Sponsors

Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (a) Age between 18 and 65 years at the time of enrollment. (b) Diagnosed with Attention-Deficit/Hyperactivity Disorder according to DSM-5 criteria. (c) A total score of >=1 on the Japanese Sensory Inventory mini (JSI-mini).

Exclusion criteria

Exclusion criteria: (a) Presence of cardiac complications. (b) Use of a cardiac pacemaker. (c) Organic or functional impairment of vision, hearing, touch, smell, or taste. (d) Strong resistance or fear toward enclosed or dark spaces. (e) Risk of adverse effects from orange aroma oil. (f) Risk of harm to self or others. (g) Planned major medication change (500 mg or greater in chlorpromazine equivalents). (h) Unlikely to complete the study (e.g., hospitalization or relocation). (i) History of conditions that may interfere with task performance (e.g., visual, hearing, language, psychiatric, or motor impairments).

Design outcomes

Primary

MeasureTime frame
Resting Respiratory Sinus Arrhythmia (RSA) before and after the intervention

Secondary

MeasureTime frame
[The following items before and after the intervention] (a) Changes in RSA in response to sensory stimulation (difference between sensory stimulation and resting baseline) (b) Difference in scores on the Conners Continuous Performance Test 3rd Edition (CPT) (c) Difference in changes in cerebral blood flow during the CPT (d) Reproduction error in the time reproduction task (e) Scores on the Multidimensional Assessment of Interoceptive Awareness (MAIA) (f) Scores on the Profile of Mood States, 2nd Edition (POMS2) (g) Scores on the State-Trait Anxiety Inventory (STAI) [The following items during the intervention] (a) RSA (at the start, at 10 minutes, at 20 minutes, and at the end) [Other background information of participants] (a) Basic demographic characteristics (b) Medical information (c) Scores on the Autism-Spectrum Quotient (AQ) (d) Scores on the Conners' Adult ADHD Rating Scales (CAARS) (e) Scores on the Adolescent/Adult Sensory Profile (A/ASP)

Countries

Japan

Contacts

Public ContactKeisuke Irie

Kyoto University Clinical Cognitive Neuroscience, Human Health Sciences, Graduate School of Medicine

irie.keisuke.8n@kyoto-u.ac.jp075-751-3968

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026